Cargando…

T-bet promotes potent antitumor activity of CD4(+) CAR T cells

Chimeric antigen receptor (CAR) therapy has shown promise against B cell malignancies in the clinic. However, limited success in patients with solid tumors has prompted the development of new CAR strategies. In this study, a B7H6-specific CAR was combined with different variants of T-bet, a transcri...

Descripción completa

Detalles Bibliográficos
Autores principales: Gacerez, Albert T, Sentman, Charles L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021366/
https://www.ncbi.nlm.nih.gov/pubmed/29515240
http://dx.doi.org/10.1038/s41417-018-0012-7